查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
新抗體療法市場:各新抗體類型，各標的適應症，各治療方法類型，各給藥途徑，各主要地區:產業趨勢與全球預測，2022年～2035年
市場調查報告書
商品編碼
1130889

新抗體療法市場:各新抗體類型，各標的適應症，各治療方法類型，各給藥途徑，各主要地區:產業趨勢與全球預測，2022年～2035年

Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035
出版日期: | 出版商: Roots Analysis | 英文 214 Pages | 商品交期: 最快1-2個工作天內

價格

本報告提供全球新抗體療法市場相關調查，提供市場概要，以及各新抗體類型，各標的適應症，各治療方法類型，各給藥途徑，各主要地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 新抗體療法:市場市場形勢

  • 分析調查手法主要的參數
  • 新抗體療法:開發平台(免疫細胞激素)
  • 新抗體療法:開發平台(免疫毒素)
  • 新抗體療法:開發平台(放射性同位素免疫複合體)
  • 新抗體療法:開發平台(及其他的抗體)
  • 新抗體療法:開發商一覽

第5章 企業簡介

  • Actinium Pharmaceuticals
  • Molecular Templates
  • Philogen
  • Roche
  • Seagen
  • Sesen bio
  • Telix Pharmaceuticals
  • Y-mAbs Therapeutics

第6章 臨床試驗分析

  • 分析研究方法及關鍵參數
  • 專注於新型抗體療法的臨床試驗清單

第7章 出版物的分析

第8章 專利分析

第9章 夥伴關係和合作

  • 專注於新型抗體療法的伙伴關係和合作清單

第10章 製藥大廠

  • 分析研究方法及關鍵參數
  • 關鍵參數的評分標準
  • 專注於新型抗體療法的主要製藥公司名單

第11章 市場規模與機會分析

  • 預測調查手法與主要的假設
  • 全球新抗體療法市場，2022年～2035年
  • 各產品預測銷售額(已上市藥物)
  • 全球新抗體療法市場，2024年及2035年:各新抗體類型
  • 全球新抗體療法市場，2026年及2035年:各標的適應症
  • 全球新抗體療法市場，2024年及2035年:各治療方法類型
  • 全球新抗體療法市場，2023年及2035年:各給藥途徑
  • 全球新抗體療法市場，2024年及2035年:各地區
  • 各產品預測銷售額(第Ⅲ相的藥物)

第12章 附錄1:表格形式的資料

第13章 附錄2:企業及組織清單

Product Code: RA100378

INTRODUCTION

Cancer is known to be one of the leading causes of deaths, worldwide. In fact, as per the annual statistics reported by the American Cancer Society (ACS) indicate that, in 2022, around 1.9 million individuals are likely to be diagnosed with various types of cancer in the US. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although several conventional treatment options, including chemotherapy, radiation therapy and surgery are available to control disease progression and keep malignant cells from spreading throughout the body, these therapies have demonstrated limited efficacy in late-stage cancers. Moreover, traditional chemotherapy and radiation therapy have negative effects on patients' quality of life due to their non-specific and extremely toxic nature. Amidst the recent initiatives undertaken to develop more targeted anti-cancer therapies, novel antibody therapies have emerged to be one of the most suitable option, having demonstrated the capability to selectively target and eliminate tumor cells. The novel antibody therapies include different classes of antibodies, which are capable of killing or inhibiting disease-causing agents. Multiple antibody formats have been engineered to enhance therapeutic efficacy and target proteins that are expressed on the surface of the affected cells. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinguish malignantly transformed cells from regular cells. Various novel antibody therapies such as immuocytokines, immunotoxins, radioimmunoconjugates and intrabodies are being investigated as a therapeutic modality across multiple clinical trials, particularly as anti-cancer agents.

Till date, six novel antibody therapies, including Adcetris® (mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, T-cell lymphoma and Hodgkin's disease), Elzonris® (Blastic plasmacytoid dendritic cell neoplasm) Lumoxiti® (Hairy cell leukemia), Pluvicto™ (Prostate cancer), Vicineum™ (Bladder cancer) and Zevalin (Lymphoma) have so far been evaluated and approved for various oncological disorders. In addition, more than 130 novel antibody therapies are being evaluated in various preclinical and clinical stages. Currently, more than 50 companies and academic / research institutes are engaged in the development of novel antibody therapies with enhanced efficacy and several promising leads are anticipated to be commercially launched over the coming decade. Over 4,500 patents related to novel antibodies have been recently filed / granted, demonstrating the innovation and continuous research efforts in this domain. In addition, multiple collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline molecules. Moreover, with the active involvement of big pharma players as well as new entrants, the development pipeline of the novel antibody therapies is likely to expand further. Driven by the growing interest of various stakeholders and encouraging clinical research results, the novel antibody therapies market is anticipated to witness steady growth over the coming years.

SCOPE OF THE REPORT

The 'Novel Antibody Therapies Market, 2022-2035: Distribution by Type of Novel Antibody (Immunocytokines, Immunotoxins and Radioisotope Immunoconjugates), Target Indication (Acute Myeloid Leukemia, Bladder Cancer, Diffuse Large B-cell Lymphoma, Graft-versus-host disease, Melanoma Prostate Cancer and Soft-tissue Sarcoma), Type of Therapy (Combination Therapy and Monotherapy), Route of Administration (Intratumoral, Intravenous and Intravesical), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035' report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the novel antibody therapies in the treatment of various diseases. The study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies. In addition to other elements, the report includes:

  • A general overview of novel antibody therapies including information on the different types of novel antibody therapies. In addition, the chapter presents details on the novel antibody therapies (antibody-directed enzyme prodrug therapy, TCR like antibodies, radioisotope immunoconjugates, immunotoxins, intracellular antibody and immunocytokines). It also features information on developmental approaches of novel antibody therapies, limitations, and future of novel antibody therapies.
  • A detailed review of the current market landscape of immunocytokines, based on several relevant parameters such as status of development (phase III, phase II, phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of cytokine, type of antigen / format, dosing frequency, type of therapy (monotherapy and combination therapy), mode of administration (injection and infusion), route of administration (intravenous, intratumoral and subcutaneous), type of therapy and target disease indication(s).
  • A detailed review of the current market landscape of immunotoxins based on several relevant parameters such as status of development (marketed, BLA registration, phase III, phase II phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of toxin, dosing frequency, type of therapy (monotherapy and combination therapy), mode of administration (injection and infusion), immunotoxin target, route of administration (intravenous, intravesical, intraperitoneal, intratumoral and intrathecal), and target disease indication(s).
  • A detailed review of the current market landscape of radioisotope immunoconjugates based on several relevant parameters such as status of development (marketed, phase III, phase II phase I and preclinical stage), type of radioisotope, route of administration (Intravenous, intracerebroventricular and intraperitoneal), type of therapy (monotherapy and combination therapy), dosing frequency, mode of administration (injection and infusion) and target disease indication(s). In addition, the chapter includes a list of novel antibody therapies with special designations. Further, the chapter presents a list of players developing novel antibody therapies along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of the key players engaged in the development of novel antibody therapies (shortlisted on the basis of number of drugs). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various novel antibody therapies, highlighting prevalent trends across different parameters, such as current trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, study design, leading industry and non-industry players (in terms of number of trials conducted), key indication(s), type of treatment, type of drug, emerging focus areas and regional distribution of trials.
  • A detailed review of more than 570 peer-reviewed, scientific articles related to research on novel antibody therapies, which have been published since 2017, based on parameters, such as year of publication, type of article, emerging focus areas, top authors, key journals, most popular publisher and copyright holders.
  • An insightful analysis of the patents filed / granted for novel antibody therapies, between 2017- 2021, based on various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading individual assignees, industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
  • An analysis of the partnerships that have been established in this domain since 2018, covering instances of acquisition, clinical trial agreement, commercialization agreement, distribution agreement, manufacturing agreement, product development agreement, product development and commercialization agreement, research and development agreement, supply agreement and other relevant type of deals.
  • An analysis of big pharma players engaged in the field of novel antibody therapies, featuring various insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of novel antibody, status of development, number of target indications, number of partnerships, number of patents and years of experience.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with novel antibody therapies market in the mid to long term. Based on parameters, such as historical sales, target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2022-2035. Our year wise projections of the current and forecasted opportunity within the novel antibody therapies market have further been segmented across type of novel antibody (immunocytokines, immunotoxins, and radioisotope immunoconjugates), target indication (acute myeloid leukemia, bladder cancer, diffuse large b-cell lymphoma, graft-versus-host disease, melanoma prostate cancer, and soft-tissue sarcoma), type of therapy (Combination Therapy and Monotherapy), route of administration (intratumoral, intravenous and intravesical), key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary research. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various non-commercial trends emerging in the industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary sources of information.

KEY QUESTIONS ANSWERED

  • Who are the leading industry and non-industry players engaged in the development of novel antibody therapies?
  • Which novel antibody therapies are being developed across early and late stages of development?
  • Which geographies are the most active in conducting clinical trials related to novel antibody therapies?
  • What is the focus area of various publications related to the novel antibody therapies?
  • Which are the leading funding institutes / centers supporting the research related to novel antibody therapies?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What are the different initiatives undertaken by big pharma players for the development of novel antibody therapies in the recent past?
  • How is the current and future market opportunity, related to novel antibody therapies likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the novel antibody therapies market in the mid to long term.

Chapter 3 provides a general overview of novel antibody therapies including information on the different types of novel antibody therapies. In addition, the chapter presents details on the novel antibody therapies (Antibody-Directed Enzyme Prodrug Therapy, TCR like Antibodies, Radioisotope Immunoconjugates, Immunotoxins, Intracellular Antibody and Immunocytokines). It also features information on developmental approaches of novel antibody therapies, limitations, and future of novel antibody therapies.

Chapter 4 provides an overview of the current market landscape of novel antibody therapies, such as immunocytokines, immunotoxins and radioisotopes immunoconjugates. In addition the chapter includes a detailed analysis of these antibody therapies based on several relevant parameters. Immunocytokines have been analyzed based on status of development (phase III, phase II, phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of cytokine, type of antigen / format, dosing frequency type of therapy(monotherapy and combination therapy), mode of administration (injection and infusion), route of administration (intravenous, Intratumoral and subcutaneous), type of therapy and target disease indication(s). Immunotoxins have been analyzed based on status of development (marketed, BLA registration, phase III, phase II phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of toxin, dosing frequency, type of therapy (monotherapy and combination therapy), mode of administration (injection and infusion), immunotoxin target, route of administration (intravenous, intravesical, intraperitoneal, Intratumoral and intrathecal) and target disease indication(s). Radioisotopes Immunoconjugates have been analyzed based on status of development (marketed, phase III, phase II phase I and preclinical stage), type of radioisotopes, route of administration (Intravenous, Intracerebroventricular and Intraperitoneal), type of therapy (monotherapy and combination therapy), dosing frequency mode of administration (injection and infusion) and target disease indication(s).

Chapter 5 includes detailed profiles of key players engaged in the development of novel antibody therapies. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.

Chapter 6 provides information on more than 550 completed, ongoing and planned clinical studies of novel antibody therapies, based on different parameters, such as trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator and study design. In addition, the chapter highlights leading industry and non-industry players, key indication(s), type of drug, emerging focus areas and regional distribution of trials.

Chapter 7 features a detailed review of more than 570 peer-reviewed, scientific articles related to research on novel antibody therapies, based on parameters, such as year of publication, emerging focus area, top authors, key research journals, popular publisher and copyright holders.(in terms of number of articles published).

Chapter 8 features an in-depth analysis of the patents that have been filed / granted for novel antibody therapies, between 2017- 2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, it includes detailed patent benchmarking and an insightful valuation analysis.

Chapter 9 features an analysis of the partnerships that have been established in this domain, covering instances of acquisition, clinical trial agreement, commercialization agreement, distribution agreement, manufacturing agreement, product development agreement, product development and commercialization agreement, research and development agreement, supply agreement and other relevant types of deals.

Chapter 10 includes an analysis of big pharma players engaged in the field of novel antibody therapies, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of novel antibody, status of development, number of target indication, number of partnerships, number of patents and years of experience.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of the novel antibody therapies market till the year 2035. It includes future sales projections of novel antibody therapies that are either marketed or are likely to be marketed within the next few years. In order to provide a detailed future outlook, our projections have been segmented across type of novel antibody (immunocytokines, immunotoxins, and radioisotope immunoconjugates), target indication (acute myeloid leukemia, bladder cancer, diffuse large b-cell lymphoma, graft-versus-host disease, melanoma prostate cancer, and soft-tissue sarcoma), type of therapy (Combination Therapy and Monotherapy), route of administration (intratumoral, intravenous and intravesical), key geographical regions (North America, Europe and Asia-Pacific).

Chapter 12 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 13 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2 Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Overview of Novel Antibody Therapies
  • 3.2. Types of Novel Antibody Therapies
    • 3.2.1. Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
      • 3.2.1.1. Mechanism of Action of ADEPT
      • 3.2.1.2. Advantages of ADEPT
      • 3.2.1.3. Disadvantages of ADEPT
    • 3.2.2. TCR like Antibodies
      • 3.2.2.1. Mechanism of Action of TCR like Antibodies
      • 3.2.2.2. Advantages of TCR like Antibodies
      • 3.2.2.3. Disadvantages of TCR like Antibodies
    • 3.2.3. Radioisotope Immunoconjugates
      • 3.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates
      • 3.2.3.2. Advantages of Radioisotope Immunoconjugates
      • 3.2.3.3. Disadvantages of Radioisotope Immunoconjugates
    • 3.2.4. Immunotoxins
      • 3.2.4.1. Mechanism of Action of Immunotoxins
      • 3.2.4.2. Advantages of Immunotoxins
      • 3.2.4.3. Disadvantages of Immunotoxins
    • 3.2.5. Intracellular Antibody
      • 3.2.5.1. Mechanism of Action of Intracellular Antibody
      • 3.2.5.2. Advantages of Intracellular Antibody
      • 3.2.5.3. Disadvantages of Intracellular Antibody
    • 3.2.6. Immunocytokines
      • 3.2.6.1. Mechanism of Action of Immunocytokines
      • 3.2.6.2. Advantages of Immunocytokines
      • 3.2.6.3. Disadvantages of Immunocytokines
  • 3.3. Therapeutic Antibodies: Development Approaches
  • 3.4. Future Perspectives

4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE

  • 4.1. Analysis Methodology and Key Parameters
  • 4.2. Novel Antibody Therapies: Development Pipeline (Immunocytokines)
    • 4.2.1. Analysis by Status of Development
    • 4.2.2. Analysis by Mechanism of Action
    • 4.2.3. Analysis by Type of Cytokine
    • 4.2.4. Analysis by Status of Development and Type of Cytokine
    • 4.2.5. Analysis by Type of Antigen / Format
    • 4.2.6. Analysis by Dosing Frequency
    • 4.2.7. Analysis by Type of Therapy
    • 4.2.8. Analysis by Mode of Administration
    • 4.2.9. Analysis by Route of Administration
    • 4.2.10. Analysis by Target Disease Indication(s)
  • 4.3. Novel Antibody Therapies: Development Pipeline (Immunotoxins)
    • 4.3.1. Analysis by Status of Development
    • 4.3.2. Analysis by Mechanism of Action
    • 4.3.3. Analysis by Type of Toxin
    • 4.3.4. Analysis by Dosing Frequency
    • 4.3.5. Analysis by Type of Therapy
    • 4.3.6. Analysis by Mode of Administration
    • 4.3.7. Analysis by Immunotoxin Target
    • 4.3.8. Analysis by Special Drug Designation
    • 4.3.9. Analysis by Route of Administration
    • 4.3.10. Analysis by Target Disease Indication(s)
  • 4.4. Novel Antibody Therapies: Development Pipeline (Radioisotope Immunoconjugates)
    • 4.4.1. Analysis by Status of Development
    • 4.4.2. Analysis by Type of Radioisotopes
    • 4.4.3. Analysis by Status of Development and Type of Radioisotopes
    • 4.4.4. Analysis by Route of Administration
    • 4.4.5. Analysis by Type of Therapy
    • 4.4.6. Analysis by Dosing Frequency
    • 4.4.7. Analysis by Mode of Administration
    • 4.4.8. Analysis by Special Drug Designation
    • 4.4.9. Analysis by Target Disease Indication(s)
  • 4.5. Novel Antibody Therapies: Development Pipeline (Other Antibodies)
  • 4.6. Novel Antibody Therapies: List of Developers
    • 4.6.1. Analysis by Type of Player
    • 4.6.2. Analysis by Company Size
    • 4.6.3. Analysis by Year of Establishment
    • 4.6.4. Analysis by Location of Headquarters (Region-wise)
    • 4.6.5. Analysis by Location of Headquarters (Country-wise)
    • 4.6.6. Analysis by Company Size and Region of Headquarters
    • 4.6.7. Leading Players: Analysis by Number of Therapeutics

5. COMPANY PROFILES

  • 5.1. Actinium Pharmaceuticals
    • 5.1.1. Company Overview
    • 5.1.2. Financial Information
    • 5.1.3. Product Portfolio
    • 5.1.4. Recent Developments and Future Outlook
  • 5.2. Molecular Templates
    • 5.2.1. Company Overview
    • 5.2.2. Financial Information
    • 5.2.3. Product Portfolio
    • 5.2.4. Recent Developments and Future Outlook
  • 5.3. Philogen
    • 5.3.1. Company Overview
    • 5.3.2. Financial Information
    • 5.3.3. Product Portfolio
    • 5.3.4. Recent Developments and Future Outlook
  • 5.4. Roche
    • 5.4.1. Company Overview
    • 5.4.2. Financial Information
    • 5.4.3. Product Portfolio
    • 5.4.4. Recent Developments and Future Outlook
  • 5.5. Seagen
    • 5.5.1. Company Overview
    • 5.5.2. Financial Information
    • 5.5.3. Product Portfolio
    • 5.5.4. Recent Developments and Future Outlook
  • 5.6. Sesen bio
    • 5.6.1. Company Overview
    • 5.6.2. Financial Information
    • 5.6.3. Product Portfolio
    • 5.6.4. Recent Developments and Future Outlook
  • 5.7. Telix Pharmaceuticals
    • 5.7.1. Company Overview
    • 5.7.2. Financial Information
    • 5.7.3. Product Portfolio
    • 5.7.4. Recent Developments and Future Outlook
  • 5.8. Y-mAbs Therapeutics
    • 5.8.1. Company Overview
    • 5.8.2. Financial Information
    • 5.8.3. Product Portfolio
    • 5.8.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

  • 6.1. Analysis Methodology and Key Parameters
  • 6.2. List of Clinical Trials Focused on Novel Antibody Therapies
    • 6.2.1. Analysis by Trial Status
    • 6.2.2. Analysis by Trial Registration Year
    • 6.2.3. Analysis by Trial Registration Year and Trial Status
    • 6.2.4. Analysis by Trial Phase
    • 6.2.5. Analysis by Trial Phase and Patients Enrolled
    • 6.2.6. Analysis by Trial Registration Year and Patients Enrolled
    • 6.2.7. Analysis by Type of Sponsor / Collaborator
    • 6.2.8. Analysis by Disease Indication(s)
    • 6.2.9. Analysis by Study Design
    • 6.2.10. Most Active Industry Players: Analysis by Number of Trials
    • 6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
    • 6.2.12. Analysis by Type of Treatment
    • 6.2.13. Analysis by Type of Drug
    • 6.2.14. Word Cloud Analysis: Emerging Focus Areas
    • 6.2.15. Analysis by Top Indication(s) and Trial Phase
    • 6.2.16. Analysis by Top Indication(s) and Leading Industry Players
    • 6.2.17. Analysis by Trial Location
    • 6.2.18. Analysis by Geography and Trial Status

7. PUBLICATION ANALYSIS

  • 7.1. Analysis Methodology and Key Parameters
  • 7.2. List of Publications Focused on Novel Antibody Therapies
    • 7.2.1. Analysis by Year of Publication
    • 7.2.2. Word Cloud Analysis: Emerging Focus Areas
    • 7.2.3. Analysis by Type of Article
    • 7.2.4. Top Authors: Analysis by Number of Publications
    • 7.2.5. Key Journals: Analysis by Number of Publications
    • 7.2.6. Key Journals: Analysis by Impact Factor
    • 7.2.7. Most Popular Publishers: Analysis by Number of Publications
    • 7.2.8. Most Popular Copyright Holders: Analysis by Number of Publications

8. PATENT ANALYSIS

  • 8.1. Analysis Methodology and Key Parameters
  • 8.2. List of Patents Focused on Novel Antibody Therapies
    • 8.2.1. Analysis by Patent Publication Year
    • 8.2.2. Year-wise Trend of Granted Patents
    • 8.2.3. Analysis by Type of Patent
    • 8.2.4. Analysis by Granted Patents and Patent Applications
    • 8.2.5. Analysis by Geography
    • 8.2.6. Analysis by CPC Symbols
    • 8.2.7. Analysis by Type of Applicant
    • 8.2.8. Analysis by Patent Age
    • 8.2.9. Word Cloud Analysis: Emerging Focus Areas
    • 8.2.10. Leading Industry Players: Analysis by Number of Patents
    • 8.2.11. Leading Non-Industry Players: Analysis by Number of Patents
    • 8.2.12. Leading Individual Assignees: Analysis by Number of Patents
    • 8.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
    • 8.2.14. Patent Valuation: Analysis Methodology and Parameters
    • 8.2.15. Patent Valuation: Analysis by Relative Valuation

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. List of Partnerships and Collaborations Focused on Novel Antibody Therapies
    • 9.1.1. Analysis by Year of Partnership
    • 9.1.2. Analysis by Type of Partnership
    • 9.1.3. Analysis by Year and Type of Partnership
    • 9.1.4. Most Popular Drug: Analysis by Number of Partnerships
    • 9.1.5. Analysis by Types of Novel Antibodies
    • 9.1.6. Analysis by Target Disease Indication(s)
    • 9.1.7. Analysis by Type of Partnership and Target Indication(s)
    • 9.1.8. Analysis by Type of Partner
    • 9.1.9. Most Active Players: Analysis by Number of Partnerships
    • 9.1.10. Most Active Players: Analysis by Type of Partnership
    • 9.1.11. Regional Analysis of Partnerships
    • 9.1.12. Intercontinental and Intracontinental Agreements

10. BIG PHARMA PLAYERS

  • 10.1 Analysis Methodology and Key Parameters
  • 10.2. Scoring Criteria for Key Parameters
  • 10.3. List of Big Pharma Players Focused on Novel Antibody Therapies
    • 10.3.1. Analysis by Supplier Strength
    • 10.3.2. Analysis by Portfolio Strength
    • 10.3.3. Analysis by Portfolio Diversity
    • 10.3.4. Benchmarking: Spider Web Analysis
    • 10.3.5. Benchmarking: Harvey Ball Analysis
    • 10.3.6. Benchmarking: Wind Rose Chart

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 11.1. Forecast Methodology and Key Assumptions
  • 11.2. Global Novel Antibody Therapies Market, 2022-2035
  • 11.3. Product-wise Sales Forecast (Marketed Drugs)
    • 11.3.1. Adcetris (Seagen)
      • 11.3.1.2. Sales Forecast
    • 11.3.2. Elzonris (Menarini Group)
      • 11.3.2.2. Sales Forecast
    • 11.3.3. Pluvicto (Novartis)
      • 11.3.3.2. Sales Forecast
  • 11.4. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Novel Antibodies
    • 11.4.1 Novel Antibody Therapies Market for Immunocytokines, 2024-2035
    • 11.4.2 Novel Antibody Therapies Market for Immunotoxin, 2023-2035
    • 11.4.3 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, 2023-2035
  • 11.5. Global Novel Antibody Therapies Market, 2026 and 2035: Distribution by Target Disease Indication(s)
    • 11.5.1 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2023-2035
    • 11.5.2 Novel Antibody Therapies Market for Bladder Cancer, 2023-2035
    • 11.5.3 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2025-2035
    • 11.5.4 Novel Antibody Therapies Market for Graft-versus-host disease, 2026-2035
    • 11.5.5 Novel Antibody Therapies Market for Melanoma, 2024-2035
    • 11.5.6 Novel Antibody Therapies Market for Prostate Cancer, 2026-2035
    • 11.5.7 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2025-2035
  • 11.6. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Therapy
    • 11.6.1. Novel Antibody Therapies Market for Combination Therapy, 2024-2035
    • 11.6.2. Novel Antibody Therapies Market for Monotherapy, 2023-2035
  • 11.7. Global Novel Antibody Therapies Market, 2023 and 2035: Distribution by Route of Administration
    • 11.7.1. Novel Antibody Therapies Market for Intratumoral Drugs, 2023-2035
    • 11.7.2. Novel Antibody Therapies Market for Intravenous Drugs, 2023-2035
    • 11.7.3. Novel Antibody Therapies Market for Intravesical Drugs, 2023-2035
  • 11.8. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Geography
    • 11.8.1. Novel Antibody Therapies Market in North America, 2023-2035
    • 11.8.2. Novel Antibody Therapies Market in Europe, 2025-2035
    • 11.8.3. Novel Antibody Therapies Market in Asia Pacific, 2023-2035
  • 11.9. Product-wise Sales Forecast (Phase III Drugs)
    • 11.9.1. Adcetris (Seagen)
      • 11.9.1.1. Target Patient Population
      • 11.9.1.2. Sales Forecast
      • 11.9.1.3. Net Present Value
      • 11.9.1.4. Value Creation Analysis
    • 11.9.2. Fibromun (Philogen)
      • 11.9.2.1. Target Patient Population
      • 11.9.2.2. Sales Forecast
      • 11.9.2.3. Net Present Value
      • 11.9.2.4. Value Creation Analysis
    • 11.9.3. Iomab-B (Actinium Pharmaceuticals)
      • 11.9.3.1. Target Patient Population
      • 11.9.3.2. Sales Forecast
      • 11.9.3.3. Net Present Value
      • 11.9.3.4. Value Creation Analysis
    • 11.9.4. Nidlegy (Philogen)
      • 11.9.4.1. Target Patient Population
      • 11.9.4.2. Sales Forecast
      • 11.9.4.3. Net Present Value
      • 11.9.4.4. Value Creation Analysis
    • 11.9.5. T-Guard (Xenikos)
      • 11.9.5.1. Target Patient Population
      • 11.9.5.2. Sales Forecast
      • 11.9.5.3. Net Present Value
      • 11.9.5.4. Value Creation Analysis
    • 11.9.6. TLX 591 (Telix Pharmaceuticals)
      • 11.9.6.1. Target Patient Population
      • 11.9.6.2. Sales Forecast
      • 11.9.6.3. Net Present Value
      • 11.9.6.4. Value Creation Analysis
    • 11.9.7. Vicinium (Sesen Bio)
      • 11.9.7.1. Target Patient Population
      • 11.9.7.2. Sales Forecast
      • 11.9.7.3. Net Present Value
      • 11.9.7.4. Value Creation Analysis

12. APPENDIX 1: TABULATED DATA

13. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

  • Table 4.1 Novel Antibody Therapies (Immunocytokines): Development Pipeline
  • Table 4.2 Novel Antibody Therapies (Immunotoxins): Development Pipeline
  • Table 4.3 Novel Antibody Therapies (Radioisotope immunoconjugates): Development Pipeline
  • Table 4.4 Novel Antibody Therapies (Other Antibodies): Development Pipeline
  • Table 4.5 Novel Antibody Therapies: List of Developers
  • Table 5.1 Actinium Pharmaceuticals: Product Portfolio
  • Table 5.2 Recent Developments and Future Outlook
  • Table 5.3 Molecular Templates: Product Portfolio
  • Table 5.4 Recent Developments and Future Outlook
  • Table 5.5 Philogen: Product Portfolio
  • Table 5.6 Recent Developments and Future Outlook
  • Table 5.7 Roche: Product Portfolio
  • Table 5.8 Recent Developments and Future Outlook
  • Table 5.9 Seagen: Product Portfolio
  • Table 5.10 Recent Developments and Future Outlook
  • Table 5.11 Sesen bio: Product Portfolio
  • Table 5.12 Recent Developments and Future Outlook
  • Table 5.13 Telix Pharmaceuticals: Product Portfolio
  • Table 5.14 Recent Developments and Future Outlook
  • Table 5.15 Y-mAbs Therapeutics: Product Portfolio
  • Table 5.16 Recent Developments and Future Outlook
  • Table 6.1 List of Clinical Trials focused on Novel Antibody Therapies (Pre 2016-2022)
  • Table 7.1 List of Publications focused on Novel Antibody Therapies (2017-2022)
  • Table 8.1 List of Patents focused on Novel Antibody Therapies (2017-2022)
  • Table 9.1 Novel Antibody Therapies: List of Partnerships and Collaborations (2014-2021)
  • Table 10.1 List of Big Pharma Player Focused on Novel Antibody Therapies
  • Table 11.1 Adcetris: Target Patient Population
  • Table 11.2 Adcetris: Net Present Value (USD Billion)
  • Table 11.3 Elzonris: Target Patient Population
  • Table 11.4 Elzonris: Net Present Value (USD Billion)
  • Table 11.5 Fibromun: Target Patient Population
  • Table 11.6 Fibromun: Net Present Value (USD Billion)
  • Table 11.7 Iomab-B: Target Patient Population
  • Table 11.8 Iomab-B: Net Present Value (USD Billion)
  • Table 11.9 Nidlegy: Target Patient Population
  • Table 11.10 Nidlegy: Net Present Value (USD Billion)
  • Table 11.11 Pluvicto: Target Patient Population
  • Table 11.12 Pluvicto: Net Present Value (USD Billion)
  • Table 11.13 T-Guard: Target Patient Population
  • Table 11.14 T-Guard: Net Present Value (USD Billion)
  • Table 11.15 TLX 591: Target Patient Population
  • Table 11.16 TLX 591: Net Present Value (USD Billion)
  • Table 11.17 Vicinium: Target Patient Population
  • Table 11.18 Vicinium: Net Present Value (USD Billion)
  • Table 12.1 Immunocytokines: Distribution by Status of Development
  • Table 12.2 Immunocytokines: Distribution by Mechanism of Action
  • Table 12.3 Immunocytokines: Distribution by Type of Cytokine
  • Table 12.4 Immunocytokines: Distribution by Status of Development and Type of Cytokine
  • Table 12.5 Immunocytokines: Distribution by Type of Antigen / Format
  • Table 12.6 Immunocytokines: Distribution by Dosing Frequency
  • Table 12.7 Immunocytokines: Distribution by Type of Therapy
  • Table 12.8 Immunocytokines: Distribution by Mode of Administration
  • Table 12.9 Immunocytokines: Distribution by Route of Administration
  • Table 12.10 Immunocytokines: Distribution by Target Disease Indication(s)
  • Table 12.11 Immunotoxins: Distribution by Status of Development
  • Table 12.12 Immunotoxins: Distribution by Mechanism of Action
  • Table 12.13 Immunotoxins: Distribution by Type of Toxin
  • Table 12.14 Immunotoxins: Distribution by Dosing Frequency
  • Table 12.15 Immunotoxins: Distribution by Type of Therapy
  • Table 12.16 Immunotoxins: Distribution by Mode of Administration
  • Table 12.17 Immunotoxins: Distribution by Immunotoxin Target
  • Table 12.18 Immunotoxins: Distribution by Special Drug Designation
  • Table 12.19 Immunotoxins: Distribution by Route of Administration
  • Table 12.20 Immunotoxins: Distribution by Target Disease Indication(s)
  • Table 12.21 Radioisotope Immunoconjugates: Distribution by Status of Development
  • Table 12.22 Radioisotope Immunoconjugates: Distribution by Type of Radioisotopes
  • Table 12.23 Radioisotope Immunoconjugates: Distribution by Status of Development and Type of Radioisotopes
  • Table 12.24 Radioisotope Immunoconjugates: Distribution by Route of Administration
  • Table 12.25 Radioisotope Immunoconjugates: Distribution by Type of Therapy
  • Table 12.26 Radioisotope Immunoconjugates: Distribution by Dosing Frequency
  • Table 12.27 Radioisotope Immunoconjugates: Distribution by Mode of Administration
  • Table 12.28 Radioisotope Immunoconjugates: Distribution by Special Drug Designation
  • Table 12.29 Radioisotope Immunoconjugates: Distribution by Target Disease Indication(s)
  • Table 12.30 Novel Antibody Therapies Developers: Distribution by Type of Players
  • Table 12.31 Novel Antibody Therapies Developers: Distribution by Company Size
  • Table 12.32 Novel Antibody Therapies Developers: Distribution by Year of Establishment
  • Table 12.33 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Region-wise)
  • Table 12.34 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Country-wise)
  • Table 12.35 Novel Antibody Therapies Developers: Distribution by Company Size and Region of Headquarters
  • Table 12.36 Leading Players: Distribution by Number of Therapeutics
  • Table 12.37 Molecular Templates: Financial Information
  • Table 12.38 Philogen: Financial Information
  • Table 12.39 Roche: Financial Information
  • Table 12.40 Seagen: Financial Information
  • Table 12.41 Sesen bio: Financial Information
  • Table 12.42 Telix Pharmaceuticals: Financial Information
  • Table 12.43 Y-mAbs Therapeutics: Financial Information
  • Table 12.44 Clinical Trial Analysis: Distribution by Trial Status
  • Table 12.45 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, (Pre-2016-April 2022)
  • Table 12.46 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, (Pre-2016- April 2022)
  • Table 12.47 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 12.48 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
  • Table 12.49 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
  • Table 12.50 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 12.51 Clinical Trial Analysis: Distribution by Disease Indication(s)
  • Table 12.52 Clinical Trial Analysis: Distribution by Study Design
  • Table 12.53 Most Active Industry Players: Distribution by Number of Trials
  • Table 12.54 Most Active Non-Industry Players: Distribution by Number of Trials
  • Table 12.55 Clinical Trial Analysis: Distribution by Type of Treatment
  • Table 12.56 Clinical Trial Analysis: Distribution by Type of Drug
  • Table 12.57 Clinical Trial Analysis: Distribution by Top Indication(s) and Trial Phase
  • Table 12.58 Clinical Trial Analysis: Distribution by Top Indication(s) and Leading Industry Players
  • Table 12.59 Clinical Trial Analysis: Distribution by Trial Location
  • Table 12.60 Clinical Trial Analysis: Distribution by Geography and Trial Status
  • Table 12.61 Publication Analysis: Distribution by Year of Publication
  • Table 12.62 Publication Analysis: Distribution by Type of Article
  • Table 12.63 Top Authors: Distribution by Number of Publications
  • Table 12.64 Key Journals: Distribution by Number of Publications
  • Table 12.65 Key Journals: Distribution by Impact Factor
  • Table 12.66 Most Popular Publishers: Distribution by Number of Publications
  • Table 12.67 Most Popular Copyright Holders: Distribution by Number of Publications
  • Table 12.68 Patent Analysis: Distribution by Patent Publication Year
  • Table 12.69 Patent Analysis: Year-wise Distribution of Granted Patents
  • Table 12.70 Patent Analysis: Distribution by Type of Patent
  • Table 12.71 Patent Analysis: Distribution by Granted Patents and Patent Applications
  • Table 12.72 Patent Analysis: Distribution by Geography
  • Table 12.73 Patent Analysis: Distribution by CPC Symbols
  • Table 12.74 Patent Analysis: Distribution by Type of Applicant
  • Table 12.75 Patent Analysis: Distribution by Patent Age
  • Table 12.76 Leading Industry Players: Distribution by Number of Patents
  • Table 12.77 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 12.78 Leading Individual Assignees: Distribution by Number of Patents
  • Table 12.79 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Table 12.80 Patent Valuation: Distribution by Relative Valuation
  • Table 12.81 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 12.82 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 12.83 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 12.84 Most Popular Drug: Distribution by Number of Partnerships
  • Table 12.85 Partnerships and Collaborations: Distribution by Types of Novel Antibodies
  • Table 12.86 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
  • Table 12.87 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication(s)
  • Table 12.88 Most Active Players: Distribution by Number of Partnership
  • Table 12.89 Partnerships and Collaborations: Distribution by Most Active Partner and Type of Partnership
  • Table 12.90 Regional Distribution of Partnerships
  • Table 12.91 Intercontinental and Intracontinental Agreements
  • Table 12.92 Global Novel Antibody Therapies Market, 2022 and 2035 (USD Billion)
  • Table 12.93 Adcetris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
  • Table 12.94 Elzonris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
  • Table 12.95 Pluvicto Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
  • Table 12.96 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Novel Antibodies
  • Table 12.97 Novel Antibody Therapies Market for Immunocytokines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.98 Novel Antibody Therapies Market for Immunotoxin, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.99 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.100 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Target Disease Indication(s)
  • Table 12.101 Novel Antibody Therapies Market for Acute Myeloid Leukemia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.102 Novel Antibody Therapies Market for Bladder Cancer, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.103 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.104 Novel Antibody Therapies Market for Graft-versus-host disease, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.105 Novel Antibody Therapies Market for Melanoma, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
  • Table 12.106 Novel Antibody Therapies Market for Prostate Cancer, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.107 Novel Antibody Therapies Market for Soft-tissue sarcoma, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.108 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Therapy
  • Table 12.109 Novel Antibody Therapies Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.110 Novel Antibody Therapies Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion))
  • Table 12.111 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Route of Administration
  • Table 12.112 Novel Antibody Therapies Market for Intratumoral Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.113 Novel Antibody Therapies Market for Intravenous Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.114 Novel Antibody Therapies Market for Intravesical Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.115 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Geography
  • Table 12.116 Novel Antibody Therapies Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.117 Novel Antibody Therapies Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.118 Novel Antibody Therapies Market in Asia Pacific Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.119 Adcetris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
  • Table 12.120 Fibromun Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
  • Table 12.121 Iomab-B Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
  • Table 12.122 Nidlegy Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
  • Table 12.123 T-Guard Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
  • Table 12.124 TLX 591 Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
  • Table 12.125 Vicinium sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)

LIST OF FIGURES

  • Figure 3.1 Types of Novel Antibody Therapies
  • Figure 3.2 Mechanism of Action of ADEPT
  • Figure 3.3 Mechanism of Action of TCR like Antibodies
  • Figure 3.4 Mechanism of Action of Radioisotope Immunoconjugates
  • Figure 3.5 Mechanism of Action of Immunotoxins
  • Figure 3.6 Mechanism of Action of Intracellular Antibody
  • Figure 3.7 Mechanism of Action of Immunocytokines
  • Figure 3.8 Therapeutic Antibodies: Development Approaches
  • Figure 4.1 Immunocytokines: Distribution by Status of Development
  • Figure 4.2 Immunocytokines: Distribution by Mechanism of Action
  • Figure 4.3 Immunocytokines: Distribution by Type of Cytokine
  • Figure 4.4 Immunocytokines: Distribution by Status of Development and Type of Cytokine
  • Figure 4.5 Immunocytokines: Distribution by Type of Antigen / Format
  • Figure 4.6 Immunocytokines: Distribution by Dosing Frequency
  • Figure 4.7 Immunocytokines: Distribution by Type of Therapy
  • Figure 4.8 Immunocytokines: Distribution by Mode of Administration
  • Figure 4.9 Immunocytokines: Distribution by Route of Administration
  • Figure 4.10 Immunocytokines: Distribution by Target Disease Indication(s)
  • Figure 4.11 Immunotoxins: Distribution by Status of Development
  • Figure 4.12 Immunotoxins: Distribution by Mechanism of Action
  • Figure 4.13 Immunotoxins: Distribution by Type of Toxin
  • Figure 4.14 Immunotoxins: Distribution by Dosing Frequency
  • Figure 4.15 Immunotoxins: Distribution by Type of Therapy
  • Figure 4.16 Immunotoxins: Distribution by Mode of Administration
  • Figure 4.17 Immunotoxins: Distribution by Immunotoxin Target
  • Figure 4.18 Immunotoxins: Distribution by Special Drug Designation
  • Figure 4.19 Immunotoxins: Distribution by Route of Administration
  • Figure 4.20 Immunotoxins: Distribution by Target Disease Indication(s)
  • Figure 4.21 Radioisotope Immunoconjugates: Distribution by Status of Development
  • Figure 4.22 Radioisotope Immunoconjugates: Distribution by Type of Radioisotopes
  • Figure 4.23 Radioisotope Immunoconjugates: Distribution by Status of Development and Type of Radioisotopes
  • Figure 4.24 Radioisotope Immunoconjugates: Distribution by Route of Administration
  • Figure 4.25 Radioisotope Immunoconjugates: Distribution by Type of Therapy
  • Figure 4.26 Radioisotope Immunoconjugates: Distribution by Dosing Frequency
  • Figure 4.27 Radioisotope Immunoconjugates: Distribution by Mode of Administration
  • Figure 4.28 Radioisotope Immunoconjugates: Distribution by Special Drug Designation
  • Figure 4.29 Radioisotope Immunoconjugates: Distribution by Target Disease Indication(s)
  • Figure 4.30 Novel Antibody Therapies Developers: Distribution by Type of Player
  • Figure 4.31 Novel Antibody Therapies Developers: Distribution by Company Size
  • Figure 4.32 Novel Antibody Therapies Developers: Distribution by Year of Establishment
  • Figure 4.33 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.34 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.35 Novel Antibody Therapies Developers: Distribution by Company Size and Region of Headquarters
  • Figure 4.36 Leading Players: Distribution by Number of Therapeutics
  • Figure 5.1 Molecular Templates: Financial Information (2016-2021)
  • Figure 5.2 Philogen: Financial Information (2017-2021)
  • Figure 5.3 Roche: Financial Information (2016-2021)
  • Figure 5.4 Seagen: Financial Information (2016-2021)
  • Figure 5.5 Sesen bio: Financial Information (2020-2021)
  • Figure 5.6 Telix Pharmaceuticals: Financial Information (2018-2021)
  • Figure 5.7 Y-mAbs Therapeutics: Financial Information (2020-2021)
  • Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, (Pre-2016-April 2022)
  • Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, (Pre-2001- April 2022)
  • Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 6.5 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
  • Figure 6.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
  • Figure 6.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 6.8 Clinical Trial Analysis: Distribution by Disease Indication(s)
  • Figure 6.9 Clinical Trial Analysis: Distribution by Study Design
  • Figure 6.10 Most Active Industry Players: Distribution by Number of Trials
  • Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Trials
  • Figure 6.12 Clinical Trial Analysis: Distribution by Type of Treatment
  • Figure 6.13 Clinical Trial Analysis: Distribution by Type of Drug
  • Figure 6.14 Word Cloud Analysis: Emerging Focus Areas
  • Figure 6.15 Clinical Trial Analysis: Distribution by Top Indication(s) and Trial Phase
  • Figure 6.16 Clinical Trial Analysis: Distribution by Top Indication(s) and Leading Industry Players
  • Figure 6.17 Clinical Trial Analysis: Distribution by Trial Location
  • Figure 6.18 Clinical Trial Analysis: Distribution by Geography and Trial Status
  • Figure 7.1 Publication Analysis: Distribution by Year of Publication
  • Figure 7.2 Word Cloud Analysis: Emerging Focus Areas
  • Figure 7.3 Publication Analysis: Distribution by Type of Article
  • Figure 7.3 Top Authors: Distribution by Number of Publications
  • Figure 7.4 Key Journals: Distribution by Number of Publications
  • Figure 7.5 Key Journals: Distribution by Impact Factor
  • Figure 7.6 Most Popular Publishers: Distribution by Number of Publications
  • Figure 7.7 Most Popular Copyright Holders: Distribution by Number of Publications
  • Figure 8.1 Patent Analysis: Distribution by Patent Publication Year
  • Figure 8.2 Patent Analysis: Year-wise Distribution of Granted Patents
  • Figure 8.3 Patent Analysis: Distribution by Type of Patent
  • Figure 8.4 Patent Analysis: Distribution by Granted Patents and Patent Applications
  • Figure 8.5 Patent Analysis: Distribution by Geography
  • Figure 8.6 Patent Analysis: Distribution by CPC Symbols
  • Figure 8.7 Patent Analysis: Distribution by Type of Applicant
  • Figure 8.8 Patent Analysis: Distribution of Patents by Age
  • Figure 8.9 Word Cloud Analysis: Emerging Focus Areas
  • Figure 8.10 Leading Industry Players: Distribution by Number of Patents
  • Figure 8.11 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 8.12 Leading Individual Assignees: Distribution by Number of Patents
  • Figure 8.13 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Figure 8.14 Patent Valuation: Distribution by Relative Valuation
  • Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 9.4 Most Popular Drug: Distribution by Number of Partnerships
  • Figure 9.5 Partnerships and Collaborations: Distribution by Types of Novel Antibodies
  • Figure 9.6 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
  • Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication(s)
  • Figure 9.8 Most Active Players: Distribution by Number of Partnership
  • Figure 9.9 Partnerships and Collaborations: Distribution by Most Active Player and Type of Partnership
  • Figure 9.10 Regional Distribution of Partnerships
  • Figure 9.11 Intercontinental and Intracontinental Agreements
  • Figure 10.1 Distribution by Supplier Strength
  • Figure 10.2 Distribution by Portfolio Strength
  • Figure 10.3 Distribution by Portfolio Diversity
  • Figure 10.4 Benchmarking: Spider Web Analysis
  • Figure 10.5 Benchmarking: Harvey Ball Analysis
  • Figure 10.6 Benchmarking: Wind Rose Chart
  • Figure 11.1 Global Novel Antibody Therapies Market, 2022-2035 (USD Billion)
  • Figure 11.2 Adcetris Sales Forecast, 2022-2035 (USD Billion)
  • Figure 11.3 Elzonris Sales Forecast, 2022-2035 (USD Billion)
  • Figure 11.4 Pluvicto Sales Forecast, 2022-2035 (USD Billion)
  • Figure 11.5 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Novel Antibodies
  • Figure 11.6 Novel Antibody Therapies Market for Immunocytokines, 2022-2035 (USD Billion)
  • Figure 11.7 Novel Antibody Therapies Market for Immunotoxin, 2022-2035 (USD Billion)
  • Figure 11.8 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, 2022-2035 (USD Billion)
  • Figure 11.9 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Target Disease Indication(s)
  • Figure 11.10 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2022-2035 (USD Billion)
  • Figure 11.11 Novel Antibody Therapies Market for Bladder Cancer, 2022-2035 (USD Billion)
  • Figure 11.12 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2022-2035 (USD Billion)
  • Figure 11.13 Novel Antibody Therapies Market for Graft-versus-host disease, 2022-2035 (USD Billion)
  • Figure 11.14 Novel Antibody Therapies Market for Melanoma, 2022-2035 (USD Billion)
  • Figure 11.15 Novel Antibody Therapies Market for Prostate Cancer, 2022-2035 (USD Billion)
  • Figure 11.16 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2022-2035 (USD Billion)
  • Figure 11.17 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Therapy
  • Figure 11.18 Novel Antibody Therapies Market for Combination Therapy, 2022-2035 (USD Billion)
  • Figure 11.19 Novel Antibody Therapies Market for Monotherapy, 2022-2035 (USD Billion)
  • Figure 11.20 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Route of Administration
  • Figure 11.21 Novel Antibody Therapies Market for Intratumoral Drugs, 2022-2035 (USD Billion)
  • Figure 11.22 Novel Antibody Therapies Market for Intravenous Drugs, 2022-2035 (USD Billion)
  • Figure 11.23 Novel Antibody Therapies Market for Intravesical Drugs, 2022-2035 (USD Billion)
  • Figure 11.24 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Geography
  • Figure 11.25 Novel Antibody Therapies Market in North America, 2022-2035 (USD Billion)
  • Figure 11.26 Novel Antibody Therapies Market in Europe, 2022-2035 (USD Billion)
  • Figure 11.27 Novel Antibody Therapies Market in Asia Pacific, 2022-2035 (USD Billion)
  • Figure 11.28 Adcetris: Target Patient Population
  • Figure 11.29 Adcetris Sales Forecast, 2022-2035 (USD Billion)
  • Figure 11.30 Fibromun: Target Patient Population
  • Figure 11.31 Fibromun Sales Forecast, 2022-2035 (USD Billion)
  • Figure 11.32 Iomab-B: Target Patient Population
  • Figure 11.33 Iomab-B Sales Forecast, 2022-2035 (USD Billion)
  • Figure 11.34 Nidlegy: Target Patient Population
  • Figure 11.35 Nidlegy Sales Forecast, 2022-2035 (USD Billion)
  • Figure 11.36 T-Guard: Target Patient Population
  • Figure 11.37 T-Guard Sales Forecast, 2022-2035 (USD Billion)
  • Figure 11.38 TLX 591: Target Patient Population
  • Figure 11.39 TLX 591 Sales Forecast, 2022-2035 (USD Billion)
  • Figure 11.40 Vicinium: Target Patient Population
  • Figure 11.41 Vicinium Forecast, 2022-2035 (USD Billion)